<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Periprocedural bleeding in patients undergoing percutaneous coronary intervention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Periprocedural bleeding in patients undergoing percutaneous coronary intervention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Periprocedural bleeding in patients undergoing percutaneous coronary intervention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Sorajja, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David R Holmes, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The advent of aggressive, multidrug antithrombotic therapy during percutaneous coronary intervention (PCI) has led to significant reductions in short- and long-term ischemic outcomes. (See  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a>.)</p><p>However, periprocedural bleeding remains a frequent complication of PCI, and its frequency and severity is related in part to the intensity of antithrombotic therapy. It is also a quality indicator of practice patterns. Initially, periprocedural bleeding was viewed as a relatively benign consequence, but data have linked the occurrence of bleeding and its treatment (ie, blood transfusion) to increased short- and long-term mortality.</p><p>This topic reviews most aspects of periprocedural bleeding among patients undergoing PCI. Gastrointestinal bleeding in this setting is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13605.html" rel="external">"Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention"</a>.)</p><p>Bleeding in relation to coronary artery bypass grafting or in association with diagnostic coronary angiography is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery", section on 'Bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/1470.html" rel="external">"Complications of diagnostic cardiac catheterization", section on 'Local vascular complications'</a> and  <a class="medical medical_review" href="/z/d/html/15202.html" rel="external">"Access-related complications of percutaneous access for diagnostic or interventional procedures"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>For the purpose of this topic, periprocedural bleeding is any bleeding that occurs during or within 48 hours of the procedure. However, some studies have including episodes of bleeding that occur during the index hospitalization. Estimates of the incidence of periprocedural bleeding during percutaneous coronary intervention (PCI) lack precision due to the use of different definitions. (See <a class="local">'Incidence'</a> below.) In addition, relevant data come from differing patient populations who were treated with varying regimens of adjunctive pharmacology. Early studies of adjunctive pharmacology in PCI utilized definitions that were extrapolated from fibrinolytic trials (such as the TIMI and GUSTO scales). These early definitions focused on occurrence of intracranial bleeds or large drops in hemoglobin [<a href="#rid1">1</a>]. In other studies, the definitions of major bleeding have included less severe, but still clinically significant, bleeds  (<a class="graphic graphic_table graphicRef71353 graphicRef77838" href="/z/d/graphic/71353.html" rel="external">table 1A-B</a>) such as the need for transfusion, bleeding requiring surgical intervention, prolonging hospital stay, or cardiac tamponade.</p><p>The heterogeneity in the definition of major bleeding at the time of PCI creates difficulty in conducting and interpreting the results of clinical research. For example, the relative safety (with regard to bleeding) of different antithrombotic agents may be difficult to ascertain when the combined safety end points across trials have different components. In an attempt to overcome this problem, there has been an attempt to develop a universal definition of bleeding. In 2011, the Bleeding Academic Research Consortium (BARC) published a consensus classification for bleeding  (<a class="graphic graphic_table graphicRef77838" href="/z/d/graphic/77838.html" rel="external">table 1B</a>) [<a href="#rid2">2</a>]. BARC has been prospectively validated and BARC types 2, 3, or 5 bleeding identify patients at increased risk of death, bleeding, and ischemic events [<a href="#rid3">3-5</a>]. In addition, BARC has a comparable predictive ability to the TIMI, GUSTO, and REPLACE-2 scales [<a href="#rid6">6</a>]. While not universally accepted, BARC provides a contemporary standard and has been commonly used in clinical trials published after 2013. </p><p class="headingAnchor" id="H3"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>Among patients enrolled in randomized trials and registries of adjunctive pharmacology for percutaneous coronary intervention (PCI), the incidence of major periprocedural bleeding ranged from 3 to 6 percent in reports published through 2008 [<a href="#rid7">7-9</a>]. More studies have found a rate closer to 2 percent [<a href="#rid10">10,11</a>]. The variability in frequency is significantly affected by access sites selected, namely radial versus femoral.</p><p>Femoral access site bleeding is the most frequent cause of periprocedural bleeding, accounting for approximately 30 to 60 percent of such events [<a href="#rid7">7,8,12</a>]. Other frequent sites of bleeding are gastrointestinal (10 to 15 percent) and retroperitoneal (5 to 12 percent). Intracranial bleeding is less common (2 to 3 percent) [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/13605.html" rel="external">"Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention"</a>.)</p><p>Access site bleeding is reduced by approximately one-half with use of the radial artery approach, although non-access related and overall bleeding may not be lower [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H4"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Several studies have examined predictors of bleeding during and after percutaneous coronary intervention (PCI) [<a href="#rid7">7-9,14,15</a>]. Consistent baseline predictors are age greater than 75 years, female sex, lower body weight, and baseline comorbidities such as anemia and chronic kidney disease [<a href="#rid16">16-18</a>]. The reasons for the predilection among women are not clear; some studies have suggested this relation becomes less evident after correction for sex-specific baseline differences such as weight, while others demonstrate a strong relation between female sex and vascular complications [<a href="#rid19">19-21</a>].</p><p>A retrospective analysis of the TRITON-TIMI 38 trial (see  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a>) evaluated potential risk factors for serious bleeding (defined as both TIMI major and TIMI minor bleeding) [<a href="#rid22">22</a>]. In addition to those mentioned above, the following were identified: glycoprotein (GP) IIb/IIIa inhibitor use, duration of the pharmacologic intervention, ST-elevation myocardial infarction, and arterial hypertension.</p><p>The most common periprocedural factors are sheath size, procedural duration, intraaortic balloon counterpulsation, complexity of the intervention, and intensity and complexity of the antithrombotic regimen. Other risk factors include left main or three vessel disease, smoking, and International Normalized Ratio (INR) &gt;2.6 in patients taking <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"</a>.)</p><p>Models to predict risk have been developed. A prognostic risk score for major bleeding during PCI has been developed with data from the REPLACE-1 and REPLACE-2 trials  (<a class="graphic graphic_table graphicRef50176" href="/z/d/graphic/50176.html" rel="external">table 2</a>) [<a href="#rid14">14,24</a>]. Using a sum of weighted integers, examination of seven variables (age &gt;55 years, female gender, glomerular filtration rate &lt;60 mL/1.73 m<sup>2</sup>, preexisting anemia, low-molecular-weight heparin with 48 hours of PCI, GP IIb/IIIa inhibitor use, and intraaortic balloon pump use) allows one to estimate the risk of bleeding with a range of 1.0 percent for no risk factors up to 5.4 percent for high-risk patients. While this prognostic score examined only patients with femoral access and has yet to be validated in less selected, "real world" registries, this assessment nevertheless does allow identification of high-risk patients who may benefit from enhanced observation after PCI. </p><p>The Academic Research Consortium (ARC) proposed clinical criteria for patients at high risk of bleeding that were validated in a study of 9623 patients undergoing PCI between 2014 and 2017 at a tertiary care center. The major criteria were, in order of descending importance: moderate or severe anemia, oral anticoagulation, malignancy, severe/end-stage chronic kidney disease, planned surgery, and thrombocytopenia. Age over 75 years, prior stroke, and prior bleeding were considered minor criteria. HBR was defined as one major or two minor criteria, with the rates of bleeding at one year being 9.1 percent in those with high bleeding risk [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Antithrombotic therapy</span><span class="headingEndMark"> — </span>Antithrombotic agents are used during percutaneous coronary intervention to decrease the risk of ischemic events. However, they are associated with an increased risk of periprocedural bleeding:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral anticoagulant therapy </strong>– Some patients scheduled for PCI are on long-term anticoagulant therapy. The approach to such patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycoprotein IIb/IIIa platelet inhibitors</strong> – The use of a GP IIb/IIIa inhibitor is associated with a 1.4- to 2.7-fold increase in risk of periprocedural bleeding [<a href="#rid7">7-9,25</a>]. (See  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'GP IIb/IIIa inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">Unfractionated heparin</a> – The risk periprocedural bleeding with unfractionated heparin (UFH) is greatest when the activated clotting time is above 300 seconds. (See <a class="local">'Bleeding parameters'</a> below and  <a class="medical medical_review" href="/z/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation"</a> and  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Other complications'</a> and  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Unfractionated heparin compared with enoxaparin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low molecular weight heparin</strong> – The rate of bleeding with low molecular weight heparin (LMWH) has been compared with that with UFH in several clinical trials, with some showing an increased rate (9.1 percent versus 7.6 percent) [<a href="#rid26">26</a>] and others showing no difference [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/1577.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies", section on 'Low molecular weight heparin'</a> and  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Unfractionated heparin compared with enoxaparin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> – Fondaparinux is a selective antithrombin that has been compared with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> for treatment of non-ST-segment elevation acute coronary syndromes in the OASIS-5 study, in which 40 percent of patients had PCI. Patients randomized to fondaparinux had lower incidences of major bleeding (3.1 percent versus 5.0 percent) and death at 30 days (2.9 percent versus 3.5 percent). However, catheter-related thrombus was statistically more frequent in the fondaparinux group (0.9 percent versus 0.4 percent). There also has been concern that the dose of enoxaparin (1.0 mg/kg twice daily, adjusted for creatinine clearance) may have been excessive [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Fondaparinux'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">Bivalirudin</a><strong> </strong>– Bivalirudin monotherapy, in place of heparin with a GP IIb/IIIa inhibitor, has been associated with a lower risk of periprocedural bleeding in several studies (see  <a class="medical medical_review" href="/z/d/html/1577.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies", section on 'Anticoagulant therapy'</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the REPLACE-2 trial of 6010 patients undergoing urgent or elective PCI, <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> with provisional IIb/IIIa blockade reduced in-hospital major bleeding (2.4 percent versus 4.1 percent) in comparison with heparin with planned IIb/IIIa blockade [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The ISAR-REACT 3 trial randomly assigned 4570 patients with stable or unstable angina who had been pretreated with 600 mg <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> ≥2 hours before PCI in double-blind fashion to heparin or <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> monotherapy. Bivalirudin led to a decrease in major bleeding at 30 days (3.1 percent versus 4.6 percent) [<a href="#rid31">31</a>]. Subsequent analysis showed that the decrease in bleeding occurred mainly in patients who were at low risk of bleeding (eg, age ≤75 years, men, body weight ≤70 kg, no renal insufficiency, single-vessel PCI), and that the patients with a lower bleeding risk were more likely to have myocardial infarction [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial randomized 13,819 patients with unstable angina or non-ST-segment elevation myocardial infarction in open-label fashion to <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> monotherapy, heparin with IIb/IIIa receptor inhibitor, or bivalirudin with IIb/IIIa receptor inhibitor. Bivalirudin monotherapy led to a statistically significant lower risk of major bleeding (3.0 percent versus 5.7 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the HORIZONS-AMI study, 3602 patients with ST-segment elevation myocardial infarction were randomly assigned to either <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> or heparin with IIb/IIIa receptor inhibitor. Bivalirudin use led to a statistically significantly, lower incidence of major bleeding (4.9 percent versus 8.3 percent), transfusion (2.1 percent versus 3.5 percent), thrombocytopenia (&lt;100,000 platelets/mm<sup>3</sup>, 1.1 percent versus 2.9 percent), and 30-day death (2.1 percent versus 3.1 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the MATRIX study, 7213 patients with acute coronary syndromes were randomly assigned to <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> or <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>; in a second randomization, patients in the bivalirudin group were also randomized to post-PCI bivalirudin or not [<a href="#rid32">32</a>]. The rate of major adverse events overall was not different according to bivalirudin therapy, but the BARC type 3 and type 5 bleeding was lower for the initial bivalirudin use versus heparin (30-day rate, 1.4 versus 2.5 percent; p&lt;0.001), and for patients who received bivalirudin post-PCI versus no post-PCI infusion (1 versus 1.8 percent; p = 0.03).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet P2Y12 receptor blockers</strong> – <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a>, <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a>, <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>, and <a class="drug drug_general" data-topicid="102219" href="/z/d/drug information/102219.html" rel="external">cangrelor</a> have been studied in patients with acute coronary syndromes, the majority of whom underwent PCI (see  <a class="medical medical_review" href="/z/d/html/1577.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies", section on 'antiplatelet therapy'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the TRITON-TIMI 38 trial, 13,608 patients were randomly assigned to <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>. Prasugrel was associated with a higher rate of major bleeding (2.4 percent versus 1.8 percent), including life-threatening bleeding (1.4 percent versus 0.9 percent) [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a>.)</p><p></p><p class="bulletIndent2">In the PLATO trial, 18,624 patients were randomly assigned to either <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>; approximately 65 percent underwent PCI. Ticagrelor led to a significantly higher rate of major bleeding (4.5 percent versus 3.8 percent) [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="102219" href="/z/d/drug information/102219.html" rel="external">Cangrelor</a>, an intravenous, reversible adenosine diphosphate receptor antagonist, has been compared with 600 mg <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> loading in two randomized trials. (See  <a class="medical medical_review" href="/z/d/html/1577.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies", section on 'Cangrelor'</a>.)</p><p></p><p class="bulletIndent2">In the CHAMPION PCI trial, <a class="drug drug_general" data-topicid="102219" href="/z/d/drug information/102219.html" rel="external">cangrelor</a> resulted in a trend for higher major bleeding using ACUITY criteria [<a href="#rid35">35</a>]. In CHAMPION PLATFORM, cangrelor was associated with a significantly higher incidence of major bleeding using the same criteria (5.5 percent versus 3.5 percent) [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dual antiplatelet therapy </strong>– Duration of dual antiplatelet therapy (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> plus P2Y12 receptor blockers) has been linked to risk of bleeding [<a href="#rid37">37-39</a>]. </p><p></p><p class="bulletIndent1">A meta-analysis of nine randomized clinical trials, consisting of 25,907 patients, showed no overall difference in net adverse clinical events between patients who received one and three months versus 6 to 12 months of dual antiplatelet therapy (hazard ratio [HR] 0.92; 95% CI 0.79-1.07). The shorter duration was associated with lower risk of any bleeding (HR 0.55; 95% CI 0.46-0.66). However, there was a nonsignificant but increasing trend of net adverse clinical events for those with more left main and left anterior descending lesions and those with ST-elevation myocardial infarction on presentation [<a href="#rid40">40</a>]. </p><p></p><p class="headingAnchor" id="H13"><span class="h1">OUTCOMES AFTER BLEEDING</span><span class="headingEndMark"> — </span>Periprocedural bleeding is associated with an increased risk of early (in-hospital and 30-day) and late mortality, major adverse cardiovascular events (MACE), and readmission for bleeding [<a href="#rid16">16,41</a>]. The discriminatory power of bleeding for predicting one-year mortality was comparable to nonfatal myocardial infarction in one study [<a href="#rid42">42</a>] and stronger than nonfatal myocardial infarction as a predictor of 30-day death in multiple studies [<a href="#rid24">24,43,44</a>].</p><p>The following studies have evaluated the relationship between periprocedural bleeding and outcome:</p><p>Among patients enrolled in randomized trials and various clinical registries, there is an approximate 3- to 10-fold increase in in-hospital and 30-day mortality for bleeding versus no bleeding [<a href="#rid8">8-10,22,45-47</a>].</p><p>For example, in a 2012 report from the (United States) National Cardiovascular Data Registry of over 3,000,000 procedures performed between 2004 and 2011, major bleeding was associated with increased in-hospital mortality (5.26 versus 1.87 percent; p&lt;.001) in a matched cohort [<a href="#rid10">10</a>]. In the entire cohort of individuals, the adjusted population attributable risk for mortality related to major bleeding was 12.1 percent. The increased risk of these events has been observed for both major and minor bleeding events, with a direct relation between severity and likelihood of poor outcomes [<a href="#rid9">9,42</a>]. </p><p>The increase in the risk of early death exists for both non-access and access site bleeding. In a meta-analysis of 25 PCI studies (n = 2,400, 645), bleeding was an independent predictor of death at both sites (risk ratios [RR] 4.06, 95% confidence interval [CI] 3.21-5.14 and 1.71, 95% CI 1.37-2.13, respectively) [<a href="#rid48">48</a>]. The increase in risk was also dependent on the site of bleeding (eg, gastrointestinal [RR = 2.78], retroperitoneal [RR = 5.87], and intracranial [RR = 22.71]).</p><p class="bulletIndent1"><span class="glyph">●</span>Periprocedural bleeding also is associated with prolonged hospital stay, intraprocedural complications (coronary perforation, embolization, dissection, ventricular fibrillation), and increased risk of myocardial infarction, stroke, renal failure, rehospitalization, and increased hospital costs [<a href="#rid8">8,10,47,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whether the mortality risk attributable to bleeding persists in late follow-up is unclear, with some studies suggesting a 2- to 4.5-fold increased risk of death at one year [<a href="#rid7">7,8,42,45</a>], with others finding no significant increase [<a href="#rid22">22</a>].</p><p></p><p>In some cases, it is not known whether bleeding is causative or simply a marker of heightened patient risk  (<a class="graphic graphic_figure graphicRef76794" href="/z/d/graphic/76794.html" rel="external">figure 1</a>) [<a href="#rid50">50</a>]. When a local effect (eg, intracranial hemorrhage with mass effect) or profound bleeding (eg, blood loss leading to severe hypotension) is present, bleeding is causative. Nevertheless, comorbidity frequently is present in patients who bleed, and these morbidities often independently correlate with risk of death and nonfatal adverse events. Although the relation of bleeding to adverse outcomes remains significant after adjustment for these morbidities, statistical modeling cannot entirely account for baseline differences between patients with and without bleeding. </p><p>Moreover, steps in management taken to address bleeding carry the potential to aggravate the risk of ischemic complications and subsequent mortality. Antithrombotic or antiplatelet therapy may be withheld in patients with bleeding, augmenting the risk of thrombotic complications such as coronary artery stent thrombosis. In the GRACE registry, patients with acute myocardial infarction who bled had a higher frequency of discontinuation of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, thienopyridines, and heparin. Patients with bleeding who had discontinuation of these medications had a higher likelihood of in-hospital death in contrast to patients in whom these medications were continued despite bleeding [<a href="#rid50">50</a>]. In addition, blood transfusion may worsen prognosis [<a href="#rid51">51</a>].</p><p>Bleeding leads to platelet activation and initiation of the clotting cascade to cause rapid local hemostasis. Mechanisms for preventing the systemic amplification of this response may be deficient in patients with vascular disease because such pathways are predominantly active within endothelial cells, potentially leading to a hypercoagulable state [<a href="#rid52">52</a>]. Erythropoietin, released in response to anemia, also may promote a prothrombotic state through activation of platelets and inducing plasminogen activator inhibitor-1, a procoagulant cytokine [<a href="#rid53">53,54</a>]. This prothrombotic state may extend beyond the acute phase of erythropoietin release. </p><p class="headingAnchor" id="H15"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The prevention of periprocedural bleeding begins with the identification of patients at high bleeding risk. (See <a class="local">'Risk factors'</a> above.)</p><p class="headingAnchor" id="H16"><span class="h2">Access site</span><span class="headingEndMark"> — </span>Radial artery access, compared with the femoral artery, is associated with fewer bleeding complications [<a href="#rid55">55-57</a>], and in patients with acute coronary syndromes, has been found to improve survival in randomized clinical trials [<a href="#rid58">58,59</a>]. For patients at increased risk of access site bleeding, it should be considered strongly. Its role in preventing periprocedural bleeding is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention", section on 'Vascular complications'</a> and  <a class="medical medical_review" href="/z/d/html/15202.html" rel="external">"Access-related complications of percutaneous access for diagnostic or interventional procedures"</a>.)</p><p>Because the vast majority of periprocedural bleeds occur at the femoral artery access site, meticulous attention to the methods for vascular access (eg, avoidance of posterior wall puncture and puncture too high or too low) by ideally using ultrasound guidance and fine needle entry, proper hemostasis, and appropriate sheath management (ie, use of smaller size, shorter duration of insertion) reduces the incidence of bleeding. (See  <a class="medical medical_review" href="/z/d/html/1470.html" rel="external">"Complications of diagnostic cardiac catheterization", section on 'Hemostasis at the femoral access site'</a> and  <a class="medical medical_review" href="/z/d/html/15192.html" rel="external">"Percutaneous arterial access techniques for diagnostic or interventional procedures", section on 'Hemostasis at the access site'</a>.)</p><p>Control of hemostasis is necessary to minimize the risk of bleeding from the femoral artery puncture site. The use of vascular closure devices has been shown to reduce the incidence of periprocedural bleeding in some [<a href="#rid11">11</a>] but not all studies [<a href="#rid9">9,60,61</a>]. We do not believe that any one device is superior to the others. The addition of ultrasound guidance to femoral access has been shown to reduce access time but not bleeding [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/1470.html" rel="external">"Complications of diagnostic cardiac catheterization", section on 'Hemostasis at the femoral access site'</a> and  <a class="medical medical_review" href="/z/d/html/15192.html" rel="external">"Percutaneous arterial access techniques for diagnostic or interventional procedures", section on 'Hemostasis at the access site'</a>.)</p><p class="headingAnchor" id="H270324319"><span class="h2">Gastrointestinal tract</span><span class="headingEndMark"> — </span>The prevention of gastrointestinal tract bleeding in patients undergoing percutaneous coronary intervention (PCI) is discussed separately. We recommend the use of proton pump inhibitors in patients at high risk of gastrointestinal bleeding. (See  <a class="medical medical_review" href="/z/d/html/13605.html" rel="external">"Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention", section on 'Proton pump inhibitors'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Bleeding parameters</span><span class="headingEndMark"> — </span>Monitoring of activated clotting time (ACT) is important for minimizing the risk of such bleeding in patients receiving <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>. For PCI without glycoprotein (GP) IIb/IIIa inhibitor, goal ACTs generally are 300 to 350 seconds. For patients receiving an IIb/IIIa receptor inhibitor, goal ACTs are lower (200 to 250 seconds) because these drugs suppress thrombin activity [<a href="#rid63">63</a>]. Of note, post-procedural unfractionated heparin (UFH) in PCI patients is associated with a ≥2.5-fold increase the risk of periprocedural bleeding [<a href="#rid60">60,64</a>]. In contrast, use of platelet reactivity parameters has not been found to associated with reduction in bleeding [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Patients on oral anticoagulants</span><span class="headingEndMark"> — </span>The approach to patients on oral anticoagulants at the time of PCI is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/101552.html" rel="external">"Periprocedural management of antithrombotic therapy in patients receiving long-term oral anticoagulation and undergoing percutaneous coronary intervention", section on 'Elective patients'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">CLINICAL MANIFESTATIONS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The clinical manifestations and diagnosis of periprocedural bleeding depend on the affected anatomic site. As mentioned above, femoral artery, gastrointestinal tract, and retroperitoneal space are the most common locations for major bleeding after percutaneous coronary intervention (PCI). Closed cavity bleeding, such as in the cranium or pericardial space, is less common but may be immediately life-threatening. (See  <a class="medical medical_review" href="/z/d/html/1470.html" rel="external">"Complications of diagnostic cardiac catheterization", section on 'Local vascular complications'</a> and <a class="local">'Incidence'</a> above and  <a class="medical medical_review" href="/z/d/html/15202.html" rel="external">"Access-related complications of percutaneous access for diagnostic or interventional procedures"</a>.)</p><p>In many patients, clinical manifestations are obvious: hematemesis or large groin hematoma. However, occult bleeding, especially retroperitoneal, should be suspected in patients with unexplained altered neurologic findings, hypotension, clinical or hemodynamic instability, or significant drops in hemoglobin or hematocrit.</p><p>In many patients, clinical manifestations are obvious: hematemesis or large groin hematoma. However, occult bleeding should be suspected in patients with unexplained altered neurologic findings, hypotension, clinical or hemodynamic instability, or significant drops in hemoglobin or hematocrit.</p><p class="headingAnchor" id="H261541657"><span class="h2">Femoral artery</span><span class="headingEndMark"> — </span>Significant bleeding in the groin may be evident by the complaint of local pain and the finding of a large hematoma, particularly in thin patients. However, in obese patients, a large femoral artery bleed may be difficult to diagnose by physical examination. Ultrasound normally suffices for evaluation and can be used to guide therapy (eg, thrombin injection for pseudoaneurysm). Retroperitoneal bleeding usually is associated with femoral access above the inguinal ligament, posterior wall femoral puncture, or inadvertent perforation of the aortoiliac vessels with guidewire or catheter advancement. Retroperitoneal bleeding may present as hypotension and bradycardia during sheath removal (it may be mistaken for hypervagotonia).</p><p>Important remote site bleeding can occur within the cranium, thorax, or abdomen. Early diagnosis requires considering the possibility. For suspected bleeding at any of these sites, computed tomography (CT) imaging of the body or head (without contrast) is recommended.</p><p class="headingAnchor" id="H261541669"><span class="h2">Retroperitoneal space</span><span class="headingEndMark"> — </span>Due to the size of the retroperitoneal space, bleeding may be clinically significant before clinical manifestations develop. Back pain and hypotension are common. We prefer angiography using femoral access (if possible) to secure the diagnosis and to potentially facilitate catheter-based treatment. Angiography can be used to facilitate the diagnosis but is also very important to control the hemorrhage with balloon inflation proximal to the site of hemorrhage. In life-threatening bleeding, inflation of a balloon placed from the contra lateral groin into the proximal iliac artery above the site of bleeding is life-saving. CT is an alternative for the diagnosis of retroperitoneal bleeding if the diagnosis is considered after the femoral catheters have been removed.</p><p class="headingAnchor" id="H261541676"><span class="h2">Gastrointestinal tract</span><span class="headingEndMark"> — </span>Significant periprocedural bleeding from the gastrointestinal tract usually occurs in patients with prior gastrointestinal lesions, such as gastric or duodenal ulcers, gastritis, or colonic polyps. Hematemesis is the most common clinical manifestation. The source of the bleed is determined by a workup of lower or upper gastrointestinal bleeding. (See  <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2547.html" rel="external">"Approach to acute lower gastrointestinal bleeding in adults"</a>.)</p><p class="headingAnchor" id="H261541683"><span class="h2">Intracranial bleeding</span><span class="headingEndMark"> — </span>Acute intracranial bleeding is a life-threatening complication. Patients may complain of acute onset of headache or vomiting or they may be observed to have mental status changes or focal deficits. (See  <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis", section on 'Clinical presentation'</a>.)</p><p>Urgent noncontrast cranial CT is the study most widely used to evaluate for the presence of acute intracerebral hemorrhage, which is evident almost immediately. In patients with neurologic findings post-angiography, urgent CT can be used to rule out bleeding and facilitate early attempts at intervention to diagnose and then treat embolic occlusion. (See  <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis", section on 'Head CT'</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Prompt recognition, timely diagnostic evaluation, achievement of hemostasis, and, when appropriate, reversal of anticoagulation, are fundamental in the management of major periprocedural bleeding. There are no established approaches to the management of patients at high risk and we use an individualized approach. We monitor high-risk patients closely. We admit unstable patients to an intensive or coronary care unit [<a href="#rid17">17</a>].</p><p>The section below discussed the general approach to major bleeding after percutaneous coronary intervention (PCI). Management of specific complications of periprocedural bleeding is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1470.html" rel="external">"Complications of diagnostic cardiac catheterization"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Reversal of anticoagulation</span><span class="headingEndMark"> — </span>Reversal of the effect of anticoagulation should be considered in patients with life-threatening bleeding, with need for open surgery to correct the etiology of bleeding, or in whom hemostasis cannot be achieved. Because reversal of anticoagulation theoretically may promote thrombogenicity, reversal should be sought only with careful consideration of the potential benefits and risks to the patient. Except in rare cases, patients with recent intracoronary stent implantation should continue to receive dual antiplatelet therapy to ameliorate the risk of acute stent thrombosis [<a href="#rid67">67</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>UFH</strong> – Intravenous protamine rapidly reverses the effects of <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> and, to a lesser extent, that of low molecular weight heparin. Protamine has been shown to facilitate early sheath removal after PCI, although one report has reported potential harm after placement of drug-eluting stents [<a href="#rid63">63,64,68</a>]. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Reversal'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">Bivalirudin</a> – For bivalirudin, there is no agent for reversal of its effects, but the therapeutic half-life of the drug is relatively short (25 min in patients with normal renal function).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a><strong> </strong>– For patients with bleeding on warfarin, either fresh frozen plasma (2 to 3 units) and/or <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> should be administered. Vitamin K, when given intravenously (0.5 to 3 mg), should be infused slowly with doses adjustment according to urgency of the bleeding, and with awareness of the potential for anaphylaxis when administered via this route. Of note, there is no difference in effectiveness of vitamin K given orally or intravenously 24 hours after administration. Thus, oral vitamin K (1 to 3 mg) can be used in patients who do not need immediate reversal of anticoagulation. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct oral anticoagulants</strong> – A discussion of the emergency treatment of bleeding in patients on anticoagulants other than heparin or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a>.)</p><p></p><p class="headingAnchor" id="H24"><span class="h2">Reversal of GP IIb/IIIa inhibitors</span><span class="headingEndMark"> — </span>Glycoprotein (GP) IIb/IIIa inhibitors increase the risk of periprocedural bleeding. Platelet transfusion is effective for reversing the effects of abciximab, but is less effective against the small molecule GP IIb/IIIa inhibitors (eg, <a class="drug drug_general" data-topicid="8918" href="/z/d/drug information/8918.html" rel="external">eptifibatide</a>, <a class="drug drug_general" data-topicid="10288" href="/z/d/drug information/10288.html" rel="external">tirofiban</a>). For the small molecule agents, the biologic half-life with dosing adjusted for creatinine clearance is approximately 2.5 hours. The management of thrombocytopenia induced by GP IIb/IIIa inhibitors is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Blood transfusion</span><span class="headingEndMark"> — </span>In patients who have undergone PCI, the rate of and risk factors for bleeding and outcomes after blood transfusion have been well studied. The optimal strategy for transfusion in these individuals has not. </p><p>In a retrospective cohort study of all patient visits from the United States (US) CathPCI Registry (2009 to 2013), the overall rate of transfusion was 2.14 percent [<a href="#rid69">69</a>]. Risk factors for transfusion included older age, female sex, hypertension, diabetes, advanced renal dysfunction, prior myocardial infarction or prior heart failure. In other studies, the use of a potent antithrombotic regimen has also been identified as a risk factor. (See  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention", section on 'Access site bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention", section on 'Anticoagulation-associated bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/15202.html" rel="external">"Access-related complications of percutaneous access for diagnostic or interventional procedures", section on 'Access site bleeding'</a>.)</p><p>A large number of studies have linked the need for transfusion to adverse outcomes, including mortality, after percutaneous coronary intervention (PCI). The following are representative studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In the British Columbia registry of PCI patients, transfused patients, in comparison to nontransfused, had significantly increased 30-day (12.6 percent versus 1.3 percent) and one-year mortality (22.3 percent versus 3.2 percent). Notably, the rates of transfusion and mortality were 40 to 50 percent lower when radial access was used in place of femoral access [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention", section on 'Radial artery access'</a> and  <a class="medical medical_review" href="/z/d/html/15192.html" rel="external">"Percutaneous arterial access techniques for diagnostic or interventional procedures", section on 'Radial artery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two separate registry studies (one of 17,901 patients from Mayo Clinic and one of 10,974 patients from Washington Hospital) demonstrated incremental risk of death with increasing transfusion requirements after PCI [<a href="#rid8">8,9</a>]. In the Mayo Clinic study, increased mortality was demonstrated in patients who received only one or two units of blood in comparison to nontransfused patients, with follow-up extending to six years after PCI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the US CathPCI Registry (2009 to 2013) referred to above, receipt of transfusion was associated with significantly increased risks of myocardial infarction, stroke, and in-hospital death (4.5 versus 1.8, 2.0 versus 0.2, and 12.5 versus 1.2 percent, respectively) [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H26"><span class="h3">Potential mechanisms of adverse outcome after blood cell transfusion</span><span class="headingEndMark"> — </span>Patients in need of blood cell transfusion after PCI have been found to be older and have greater comorbidity than nontransfused patients. Adjustment for these baseline characteristics using either multivariate models and/or propensity analyses has shown transfusion to be an independent predictor of both in-hospital and one-year survival. While statistical methods cannot fully account for retrospective bias, several explanations, in addition to bias, have been proposed to help explain the link between blood transfusion and excess mortality:</p><p class="bulletIndent1"><span class="glyph">●</span>Rises in hemoglobin level with blood cell transfusion increase oxygen delivery, but measures of tissue oxygenation do not change or, in fact, may decrease. Storage of red blood cells may lead to less deformability and more fragility of the cell, reduced nitric oxide activity (resulting in less vasodilatation during decoupling of oxygen delivery), and depletion of 2,3-diphosphoglyceric acid (leading to reduced tissue extraction of oxygen) [<a href="#rid71">71-75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transfusion may be prothrombotic, due to enhancement of procoagulant protein plasminogen activator inhibitor (PAI)-1 content during cell storage, acute platelet release of CD40 ligand during transfusion, release of adenosine diphosphate from stored red blood cells that leads to platelet activation, and relative deficiencies in nitric oxide in the transfused blood products [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemolytic reactions and the consequences of large-volume transfusion (eg, coagulopathy, electrolyte disturbances) may lead to increased mortality [<a href="#rid77">77</a>].</p><p></p><p>The physiologic changes in red blood cells that occur with storage are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'RBC age/storage duration effect on clinical outcomes'</a>.) </p><p class="headingAnchor" id="H27"><span class="h3">Recommendations for blood transfusion</span><span class="headingEndMark"> — </span>General recommendations for transfusion in patients with cardiovascular disease are found elsewhere. Briefly, we suggest transfusion for stable patients with coronary artery disease when the hemoglobin falls below 7 to 8 g/dL; for patients with acute coronary syndrome, we suggest transfusion when the hemoglobin falls below 8 to 10 g/dL. (See  <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Acute and chronic cardiovascular disease'</a> and  <a class="medical medical_review" href="/z/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Red cell transfusion'</a>.)</p><p>The optimal transfusion strategy for patients who have undergone PCI has not been well-studied, but the general recommendations presented above are a reasonable starting point. The rate and expected duration of bleeding, as well as the cardiovascular instability of the patient, should be considered in decision making. We feel that there is insufficient evidence to recommend specific hemoglobin (or hematocrit) targets for patients who have undergone PCI.</p><p>For patients with periprocedural bleeding and who have severe symptoms of angina or dyspnea (class ≥III or lifestyle impairment) or have evidence of myocardial ischemia despite revascularization, it is reasonable to transfuse when the hemoglobin falls below 10 g/dL. Transfusion may be reasonable at higher hemoglobin levels in patients for whom the rate of bleeding is fast and likely to continue. The clinical threshold for transfusion may be lower in those with acute coronary syndromes, as the risk of anemia appears to be greater in these patients [<a href="#rid14">14,78</a>]. In the absence of such findings, the net benefit may be minimal with significant potential for harm. One exception may be an asymptomatic patient who is at high risk from rebleeding from a noncompressible site, in whom a greater reserve of red cell mass may be desired.</p><p>In a Canadian study of 357 critically ill patients with cardiovascular disease, a restrictive transfusion policy (transfusion for hgb &lt;7.0 g/dL), in comparison to a liberal policy (transfusion for hgb &lt;10.0 g/dL), was associated with less multiorgan dysfunction but no difference in 30-day mortality (23 percent for both groups) [<a href="#rid79">79,80</a>]. The authors did report a trend toward less 30-day survival in the restrictive policy group among the patients with acute myocardial infarction or unstable angina (21 percent versus 26 percent), but this difference was not significant. In a separate study of patients with acute coronary syndromes, the predicted probability of 30-day death was higher with transfusion at nadir hematocrit values above 25 percent [<a href="#rid81">81</a>]. Conversely, another study of older adult patients with acute myocardial infarction demonstrated mortality benefit for transfusion for hematocrit less than 30 percent [<a href="#rid78">78</a>].</p><p>The general discussion of indications for red cell transfusion is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence and risk factors </strong>– Periprocedural bleeding occurs in 3 to 6 percent of cases. Risk factors include age greater than 75 years, female gender, baseline anemia, and chronic kidney disease, sheath size, procedural duration, intraaortic balloon pump placement, complexity of the intervention, and intensity and complexity of the antithrombotic regimen. (See <a class="local">'Incidence'</a> above and <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes </strong>– Periprocedural bleeding is associated with adverse outcomes including a fourfold or greater increase in early and late mortality  (<a class="graphic graphic_figure graphicRef76794" href="/z/d/graphic/76794.html" rel="external">figure 1</a>). The cause of adverse outcomes is often multifactorial and includes the local effects of the bleed, excess patient morbidity that is frequently present in those who bleed, and potential harm from therapy taken to address occurrence of bleeding. (See <a class="local">'Outcomes after bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– This includes identification of patients at high risk; meticulous attention to the access site including consideration of radial access; and proper use of the activated clotting time for patients receiving heparin. (See <a class="local">'Prevention'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Management of periprocedural bleeding must be individualized as each intervention aimed at terminating the bleeding may adversely impact outcome. Interventions include reversal of anticoagulation and glycoprotein (GP) IIb/IIIa inhibitors, and blood transfusion. While blood transfusion is often considered for patients who bleed, it has been linked to increased mortality after percutaneous coronary intervention (PCI). Therefore, blood transfusion should only be undertaken after careful consideration of the potential benefit and risks to the patient. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Periprocedural and long-term gastrointestinal bleeding are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13605.html" rel="external">"Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11:1.</a></li><li><a class="nounderline abstract_t">Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123:2736.</a></li><li><a class="nounderline abstract_t">Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 2012; 125:1424.</a></li><li><a class="nounderline abstract_t">Vranckx P, Leonardi S, Tebaldi M, et al. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. Eur Heart J 2014; 35:2524.</a></li><li><a class="nounderline abstract_t">Cao D, Mehran R, Dangas G, et al. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. J Am Coll Cardiol 2020; 75:2711.</a></li><li><a class="nounderline abstract_t">Kikkert WJ, van Geloven N, van der Laan MH, et al. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications. J Am Coll Cardiol 2014; 63:1866.</a></li><li><a class="nounderline abstract_t">Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007; 100:1364.</a></li><li><a class="nounderline abstract_t">Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92:930.</a></li><li><a class="nounderline abstract_t">Doyle BJ, Ting HH, Bell MR, et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv 2008; 1:202.</a></li><li><a class="nounderline abstract_t">Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 2013; 309:1022.</a></li><li><a class="nounderline abstract_t">Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA 2010; 303:2156.</a></li><li><a class="nounderline abstract_t">Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011; 377:1409.</a></li><li><a class="nounderline abstract_t">Baklanov DV, Kim S, Marso SP, et al. Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry. Circ Cardiovasc Interv 2013; 6:347.</a></li><li><a class="nounderline abstract_t">Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28:1936.</a></li><li><a class="nounderline abstract_t">Iijima R, Ndrepepa G, Mehilli J, et al. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J 2009; 30:290.</a></li><li><a class="nounderline abstract_t">Rao SV, Dai D, Subherwal S, et al. Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv 2012; 5:958.</a></li><li><a class="nounderline abstract_t">Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32:1854.</a></li><li><a class="nounderline abstract_t">Pellaton C, Cayla G, Silvain J, et al. Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial. Am Heart J 2015; 170:778.</a></li><li><a class="nounderline abstract_t">Fernandes LS, Tcheng JE, O'Shea JC, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. J Am Coll Cardiol 2002; 40:1085.</a></li><li><a class="nounderline abstract_t">Chacko M, Lincoff AM, Wolski KE, et al. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J 2006; 151:1032.e1.</a></li><li><a class="nounderline abstract_t">Pandie S, Mehta SR, Cantor WJ, et al. Radial Versus Femoral Access for Coronary Angiography/Intervention in Women With Acute Coronary Syndromes: Insights From the RIVAL Trial (Radial Vs femorAL access for coronary intervention). JACC Cardiovasc Interv 2015; 8:505.</a></li><li><a class="nounderline abstract_t">Hochholzer W, Wiviott SD, Antman EM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation 2011; 123:2681.</a></li><li><a class="nounderline abstract_t">Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103:13.</a></li><li><a class="nounderline abstract_t">Mehran R, Pocock S, Nikolsky E, et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv 2011; 4:654.</a></li><li><a class="nounderline abstract_t">Kastrati A, Mehilli J, Schühlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232.</a></li><li><a class="nounderline abstract_t">Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45.</a></li><li><a class="nounderline abstract_t">Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355:1006.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003; 41:20.</a></li><li><a class="nounderline abstract_t">Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464.</a></li><li><a class="nounderline abstract_t">Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853.</a></li><li><a class="nounderline abstract_t">Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688.</a></li><li><a class="nounderline abstract_t">Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med 2015; 373:997.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001.</a></li><li><a class="nounderline abstract_t">Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045.</a></li><li><a class="nounderline abstract_t">Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361:2318.</a></li><li><a class="nounderline abstract_t">Bhatt DL. Prasugrel in clinical practice. N Engl J Med 2009; 361:940.</a></li><li><a class="nounderline abstract_t">Watanabe H, Domei T, Morimoto T, et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019; 321:2414.</a></li><li><a class="nounderline abstract_t">Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371:2155.</a></li><li><a class="nounderline abstract_t">Toyota T, Shiomi H, Morimoto T, et al. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. PLoS One 2017; 12:e0174502.</a></li><li><a class="nounderline abstract_t">Park DY, Wang P, An S, et al. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis. Am Heart J 2022; 251:101.</a></li><li><a class="nounderline abstract_t">Suh JW, Mehran R, Claessen BE, et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2011; 58:1750.</a></li><li><a class="nounderline abstract_t">Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51:690.</a></li><li><a class="nounderline abstract_t">Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49:1362.</a></li><li><a class="nounderline abstract_t">Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 55:2556.</a></li><li><a class="nounderline abstract_t">Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229.</a></li><li><a class="nounderline abstract_t">Jani SM, Smith DE, Share D, et al. Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention. Clin Cardiol 2007; 30:II49.</a></li><li><a class="nounderline abstract_t">Yatskar L, Selzer F, Feit F, et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv 2007; 69:961.</a></li><li><a class="nounderline abstract_t">Kwok CS, Khan MA, Rao SV, et al. Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Interv 2015; 8.</a></li><li><a class="nounderline abstract_t">Kim P, Dixon S, Eisenbrey AB, et al. Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol 2007; 30:II35.</a></li><li><a class="nounderline abstract_t">Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 2007; 116:2793.</a></li><li><a class="nounderline abstract_t">Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009; 53:2019.</a></li><li><a class="nounderline abstract_t">Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106:2605.</a></li><li><a class="nounderline abstract_t">Taylor JE, Henderson IS, Stewart WK, Belch JJ. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 1991; 338:1361.</a></li><li><a class="nounderline abstract_t">Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59:538.</a></li><li><a class="nounderline abstract_t">Louvard Y, Benamer H, Garot P, et al. Comparison of transradial and transfemoral approaches for coronary angiography and angioplasty in octogenarians (the OCTOPLUS study). Am J Cardiol 2004; 94:1177.</a></li><li><a class="nounderline abstract_t">Pristipino C, Trani C, Nazzaro MS, et al. Major improvement of percutaneous cardiovascular procedure outcomes with radial artery catheterisation: results from the PREVAIL study. Heart 2009; 95:476.</a></li><li><a class="nounderline abstract_t">Mamas MA, Anderson SG, Carr M, et al. Baseline bleeding risk and arterial access site practice in relation to procedural outcomes after percutaneous coronary intervention. J Am Coll Cardiol 2014; 64:1554.</a></li><li><a class="nounderline abstract_t">Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol 2012; 60:2481.</a></li><li><a class="nounderline abstract_t">Bernat I, Horak D, Stasek J, et al. ST-segment elevation myocardial infarction treated by radial or femoral approach in a multicenter randomized clinical trial: the STEMI-RADIAL trial. J Am Coll Cardiol 2014; 63:964.</a></li><li><a class="nounderline abstract_t">Koreny M, Riedmüller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA 2004; 291:350.</a></li><li><a class="nounderline abstract_t">Ellis SG, Bhatt D, Kapadia S, et al. Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention. Catheter Cardiovasc Interv 2006; 67:541.</a></li><li><a class="nounderline abstract_t">Nguyen P, Makris A, Hennessy A, et al. Standard versus ultrasound-guided radial and femoral access in coronary angiography and intervention (SURF): a randomised controlled trial. EuroIntervention 2019; 15:e522.</a></li><li><a class="nounderline abstract_t">Ducas J, Chan MC, Miller A, Kashour T. Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients. Catheter Cardiovasc Interv 2002; 56:196.</a></li><li><a class="nounderline abstract_t">Cosgrave J, Qasim A, Latib A, et al. Protamine usage following implantation of drug-eluting stents: a word of caution. Catheter Cardiovasc Interv 2008; 71:913.</a></li><li><a class="nounderline abstract_t">Nishikawa M, Isshiki T, Kimura T, et al. No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis. Thromb Res 2015; 136:947.</a></li><li><a class="nounderline abstract_t">Wang TY, Henry TD, McCoy LA, et al. Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. Am Heart J 2015; 170:706.</a></li><li><a class="nounderline abstract_t">Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49:734.</a></li><li><a class="nounderline abstract_t">Briguori C, Di Mario C, De Gregorio J, et al. Administration of protamine after coronary stent deployment. Am Heart J 1999; 138:64.</a></li><li><a class="nounderline abstract_t">Sherwood MW, Wang Y, Curtis JP, et al. Patterns and outcomes of red blood cell transfusion in patients undergoing percutaneous coronary intervention. JAMA 2014; 311:836.</a></li><li><a class="nounderline abstract_t">Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 2008; 94:1019.</a></li><li><a class="nounderline abstract_t">Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116:393.</a></li><li><a class="nounderline abstract_t">Almac E, Ince C. The impact of storage on red cell function in blood transfusion. Best Pract Res Clin Anaesthesiol 2007; 21:195.</a></li><li><a class="nounderline abstract_t">Anniss AM, Sparrow RL. Variable adhesion of different red blood cell products to activated vascular endothelium under flow conditions. Am J Hematol 2007; 82:439.</a></li><li><a class="nounderline abstract_t">Berezina TL, Zaets SB, Morgan C, et al. Influence of storage on red blood cell rheological properties. J Surg Res 2002; 102:6.</a></li><li><a class="nounderline abstract_t">Allen BW, Piantadosi CA. How do red blood cells cause hypoxic vasodilation? The SNO-hemoglobin paradigm. Am J Physiol Heart Circ Physiol 2006; 291:H1507.</a></li><li><a class="nounderline abstract_t">Twomley KM, Rao SV, Becker RC. Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions. J Thromb Thrombolysis 2006; 21:167.</a></li><li><a class="nounderline abstract_t">Janatpour K, Holland PV. Noninfectious serious hazards of transfusion. Curr Hematol Rep 2002; 1:149.</a></li><li><a class="nounderline abstract_t">Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345:1230.</a></li><li><a class="nounderline abstract_t">Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409.</a></li><li><a class="nounderline abstract_t">Hébert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001; 29:227.</a></li><li><a class="nounderline abstract_t">Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292:1555.</a></li></ol></div><div id="topicVersionRevision">Topic 1573 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3121710" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670242" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22344040" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24755007" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32466887" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657697" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17950791" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14556868" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463301" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23483177" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Association between bleeding events and in-hospital mortality after percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20516416" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21470671" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23922144" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575270" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147609" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22995883" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21715717" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26386802" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12354432" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16644331" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25907080" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Radial Versus Femoral Access for Coronary Angiography/Intervention in Women With Acute Coronary Syndromes: Insights From the RIVAL Trial (Radial Vs femorAL access for coronary intervention).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606391" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20062939" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700252" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724302" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15238590" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16957147" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12570939" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537663" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of fondaparinux and enoxaparin in acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588269" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703471" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26324049" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17982182" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prasugrel versus clopidogrel in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717846" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ticagrelor versus clopidogrel in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915221" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Platelet inhibition with cangrelor in patients undergoing PCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19605807" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prasugrel in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31237644" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25399658" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28931015" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35654162" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21996385" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18279731" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17394970" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20513595" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A risk score to predict bleeding in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18354101" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Duration of red-cell storage and complications after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18228652" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17421023" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25825007" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18228650" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025530" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19477350" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994286" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Directing thrombin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1682739" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Erythropoietin and spontaneous platelet aggregation in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14499855" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The cardiovascular effects of erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15518616" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparison of transradial and transfemoral approaches for coronary angiography and angioplasty in octogenarians (the OCTOPLUS study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036757" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Major improvement of percutaneous cardiovascular procedure outcomes with radial artery catheterisation: results from the PREVAIL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25301457" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Baseline bleeding risk and arterial access site practice in relation to procedural outcomes after percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22858390" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24211309" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : ST-segment elevation myocardial infarction treated by radial or femoral approach in a multicenter randomized clinical trial: the STEMI-RADIAL trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734598" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16547938" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31113763" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Standard versus ultrasound-guided radial and femoral access in coronary angiography and intervention (SURF): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12112912" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18383161" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Protamine usage following implantation of drug-eluting stents: a word of caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26460279" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26386794" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17291948" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10385766" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Administration of protamine after coronary stent deployment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24570247" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Patterns and outcomes of red blood cell transfusion in patients undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18332059" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736773" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prudent strategies for elective red blood cell transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17650772" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The impact of storage on red cell function in blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133424" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Variable adhesion of different red blood cell products to activated vascular endothelium under flow conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11792145" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Influence of storage on red blood cell rheological properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16751292" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : How do red blood cells cause hypoxic vasodilation? The SNO-hemoglobin paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16622613" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12901137" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Noninfectious serious hazards of transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11680442" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Blood transfusion in elderly patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9971864" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11246298" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15467057" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
